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Background: Attention deﬁcit-hyperactivity disorder (ADHD) is the most common
neuro-developmental disorder in childhood. Its pharmacologic treatment mostly includes
methylphenidate, yet many parents seek alternative, “natural,” therapeutic options,
commonly omega-3 fatty acids. Previous studies of supplementation with ﬁsh oil or
long-chain omega-3 fatty acids to children with ADHD yielded mixed results. The use of
alpha-linolenic acid (ALA), a medium-chained, plant-based omega-3 fatty acid (18:3 n-3),
has not been sufﬁciently examined in this population.
Methods: Forty untreated children with ADHD, aged 6–16 years, were randomized to
receive either 2 g/day of oil containing 1 g ALA or placebo, for 8 weeks. Before and after
supplementation, the children underwent a physician assessment of ADHD symptoms
and a computerized continuous performance functions test. The children’s parents and
teachers ﬁlled out Conners’ and DSM questionnaires.
Results: Seventeen (42.5%) children completed the study, eight in the supplementation
group, nine in the placebo group. Main drop-out reasons were capsule size, poor
compliance, and a sense of lack of effect. No signiﬁcant difference was found in any of
the measured variables tested before and after supplementation, in both study groups.
No between-group difference was found in the changes of the various measures of ADHD
symptoms throughout the study period.
Conclusion: Supplementation of 2 g/day of oil containing 1 g ALA did not signiﬁcantly
reduce symptoms in children with ADHD. Future studies in this ﬁeld should consider an
alternative method to deliver the oil, a higher dose, and a larger sample size.
Keywords: fattyAcids, omega-3, attention, hyperactivity,ADHD, linolenic acids
INTRODUCTION
Attention-deﬁcit hyperactivity disorder (ADHD) is a childhood
onset disorder with a relatively high global prevalence, ranging
from 2.2–17.8% (Skounti etal., 2007). ADHD is considered the
mostcommonneuro-behavioraldisorderofchildhood,andoneof
themostprevalentchronichealthconditionsaffectingschool-aged
children (Wolraich etal., 2011).
The pharmacologic treatment of ADHD mostly includes
methylphenidate (Wolraich etal., 2011). Surprisingly, one study
fromIsraelfoundthattheprevalenceofmethylphenidateprescrip-
tionuseinthepopulationwasonly2.5%–amuchsmallerratethan
theestimatedprevalenceofADHDinIsrael(Vinkeretal.,2006).A
possible explanation as to why a large proportion of children with
ADHD are not adequately treated could be the stigmatization of
methylphenidate. Indeed, many parents continuously seek alter-
native,“natural,”therapeutic options other than methylphenidate
(Berger etal., 2008). Omega-3 fatty acids are among the most
common dietary supplements used in children with ADHD. The
basisforthistreatmentstemsfromstudiesthatidentiﬁedlowlevels
of omega-3 fatty acids in plasma phospholipids or red blood cell
membranes of children withADHD (Mitchell etal.,1987; Stevens
etal.,1995;Antalis etal., 2006).
Several trials of supplementation with ﬁsh oil or long-chain
omega-3 fatty acids [mostly eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA)] to children with ADHD have been
conducted, and yielded mixed results. Systematic reviews and
meta-analyses on this topic summarized that there is currently
no consensus that omega-3 fatty acids inﬂuence ADHD symp-
toms(Richardson,2006;Chalon,2009;RazandGabis,2009;Bloch
and Qawasmi, 2011; Gillies etal., 2012). One possible mechanism
suggested for the common lack of effect is a relatively poor incor-
poration of these fatty acids into the brain. In a pioneering study,
Vaisman etal. (2008) showed that consumption of EPA and DHA
that were incorporated into phospholipids, resulted in higher
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circulatinglevelsandbetterexecutivefunctioninginchildrenwith
ADHD, as compared with ﬁsh oil. The authors identiﬁed signif-
icant correlations between the chemical changes and the clinical
effects. Another supplementation study with long chain omega-3
fatty acids conjugated to phosphatidylserine, in order to improve
their absorption,also showed improved behavior of children with
ADHD (Manor etal., 2012).
Fewer trials examined the effect of the plant-based alpha-
linolenic acid (ALA), the parent medium-chain omega-3 fatty
acid, on ADHD symptoms. In one published study, 200 mg ALA
administered as ﬂaxseed oil together with vitamin C were given
to children with ADHD (Joshi etal., 2006). The authors noted
increased levels of circulating EPA and DHA, with improvements
inparent-ratedADHDsymptomsofimpulsivity,restlessness,inat-
tention,andself-control.Yetthelackofcontrolgroupinthisstudy,
therelyingonparentreportonly,andtheconcomitantadditionof
vitaminC,preventfromdrawingclearconclusionsontheeffectof
ALA alone. In another study,children with ADHD received either
a supplement containing 120 mg of ALA and 480 mg of linoleic
acid and, or vitamin C as placebo, for 7 weeks (Raz etal., 2009).
Treatment effects were measured using questionnaires and a com-
puterizedtestof attention,anddidnotdiffersigniﬁcantlybetween
groups. Of note, these authors administered a relatively low dose
of ALA,whilealsosupplementingwithahigherdoseof theparent
fattyacidof theomega-6familywhichcouldinhibitconversionof
ALA to the long chain omega-3 fatty acids through competition
on the same enzymes. It still remains unknown whether supple-
mentation of a higher dose of ALA could affectADHD symptoms
more than placebo.
Theaimofthecurrentstudywastoexamineifsupplementation
with an ALA-rich sage oil can improve symptoms in children and
adolescents diagnosed with ADHD.
MATERIALS AND METHODS
PARTICIPANTS
The study population included 40 children and adolescents aged
6–16 years, recently diagnosed with ADHD, who were drug naïve
and untreated, from two ambulatory ADHD specialty clinics in
Israel. Exclusion criteria were refusal to undergo any or all of
the testing procedures or to take the designated supplement; a
history of chronic health conditions other than ADHD; or use
of any chronic medications or dietary supplements, speciﬁcally
methylphenidate or fatty acid/ﬁsh oil supplements. The study was
approved by the Institutional Review Board of Hadassah Medical
Center, Jerusalem, Israel, conducted according to the Declaration
ofHelsinki,andregisteredinaclinicaltrialsregistrybeforerecruit-
ment (#NCT00874536). At least one parent signed an informed
consent form, and each participant verbally agreed to participate.
INTERVENTION
The study participants were randomized 1:1 to receive either
2 g/day of sage oil or an identical appearing lactose placebo in
gel capsules. Participants were instructed to consume two gel cap-
sulesdaily. Thecompositionof sageoilvariesslightlybycropyear,
and is 50–54% ALA, 20–23% oleic acid, 16–18% linoleic acid, 6–
7% palmitic acid, and 2–3% stearic acid (Tulukcu etal., 2012).
This corresponds to a supplementation of 1 g/day of ALA, a dose
that had been shown previously in adults to elevate the concen-
trations of omega-3 fatty acids (Barceló-Coblijn etal., 2008). The
supplementation period lasted 8 weeks.
RANDOMIZATION
Both types of capsules were supplied in identical amounts in
solidplasticbottles. Thebottleswerenumberedconsecutivelyand
coded by a person uninvolved in the study, and each participant
receivedthreebottlesthatcontainedallpillsnecessaryforthestudy
duration.EachADHDclinicreceivedhalfofthebottles,numbered
consecutively. The children that agreed to participate in the study
received their designated bottles in consecutive order. All study
participants, parents, teachers, and study personnel were blinded
to the allocation until completion of all data collection.
OUTCOMES AND DATA COLLECTION
The primary outcomes at study end were ADHD symp-
toms, as assessed by validated questionnaires and a comput-
erized continuous performance test (CPT, see below). Each
child met the criteria for ADHD according to Diagnostic and
Statistical Manual of Mental Disorders (DSM)-IV-TR criteria
(American Psychiatric Association, 2000), as assessed by a physi-
cian certiﬁed in ADHD diagnosis and treatment.
The diagnostic procedure included an interview with the child
and parents, ﬁling of DSM-based ADHD diagnostic question-
naires, and a medical and neurological examination. Parents and
teachers ﬁlled the appropriate Conners’ rating scales (Conners,
1997a,b).
We used the MOXO-CPT, which is a standardized computer-
ized test designed to diagnose ADHD-related symptoms (Berger
etal., 2009). The total duration of the test is 15 min, and it is
composed of eight levels of 53 trials each. In each trial, a stim-
ulus in the form of a cartoon picture (designated as “target”
or “non-target”) is presented for 500, 1000, or 3000 ms, fol-
lowed by a “void” period of the same duration, during which
the tested individual should respond by pressing the keyboard
“space” bar as quickly as possible. In each level, 33 target and
20 non-target stimuli are presented. The tested participant is
instructed not to respond to any other stimuli except the target,
and not to press any other key but the space bar, and only once.
The response timing and accuracy is measured after each stim-
ulus. The test includes distracting stimuli that are presented to
the tested participant. These distractors are short animated video
clips, containing visual, and auditory features. Six different dis-
tractors are included, each of them could appear as only visual,
only auditory,or as a combination of both. Each distractor is pre-
sented for a different duration ranging from 3.5–14.8 s, with a
ﬁxed interval of 0.5 s between two distractors. Distractor onset is
not synchronized with target/non-target onset, and could there-
fore appear either during the stimulus events or during the void
period. The burden of the distracting stimuli increases during the
test.
The MOXO-CPT measures four performance indices: atten-
tion, timing, impulsivity, and hyperactivity. The attention index
corresponds to the number of correct space bar keystrokes in
responsetoatargetstimulus. Thisindexisconsideredapuremea-
sure of sustained attention, because it measures correct responses
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independently of the response time. The timing index is the num-
ber of correct responses given quickly, still within the period that
the target stimulus is present on screen. The impulsivity index is
the number of responses performed following a non-target stim-
ulus. The hyperactivity index is the total number of commission
responsesthatarenotcodedasimpulsiveresponses(e.g.,multiple
keystrokes in response to a target stimulus, responses performed
in the void period after a non-target stimulus, random key press-
ing). Other measures of the MOXO-CPT are described in detail
elsewhere (Berger etal., 2013; Cassuto etal., 2013).
The same assessment tools were used after 8 weeks of supple-
mentation in both groups. At this ﬁnal assessment visit, missing
pills in the bottles were counted,to assess adherence.
STATISTICAL ANALYSIS
The differences in questionnaire scores and CPT results between
baseline to end-of-study values within each group were compared
by theWilcoxon signed-ranks test. The differences in clinical data,
questionnaire scores, and CPT results between study groups at
baseline and at trial end were compared by the Mann–Whitney
U Test. The between-group differences in the changes of ques-
tionnaire scores and CPT results were also compared by the
Mann–WhitneyU Test.ProportionswerecomparedusingFisher’s
exact test. Statistical signiﬁcance was deﬁned as a two-sided
p-value <0.05.
RESULTS
Twenty children were included in each group, and received
their designated supplement. After 8 weeks, only 17 participants
remained in the study, and underwent the post-supplementation
assessment: nine in placebo group (six males, three females,
mean age 10.9 ± 2.3 years) and eight in the oil group (four
males, four females, mean age 11.1 ± 3.0 years). Reasons for
dropout were difﬁculty to take the capsules due to size or taste
(n=7), a subjective sense of lack of effect (n = 4), loss of con-
tact (n = 5), or lack of interest to perform the second assessment
(n = 7). None of the participants complained about the most
common intolerance to ﬁsh oils, namely a “ﬁshy” smell and
aftertaste.
PARENT QUESTIONNAIRES
Table 1 presents data from parent questionnaires, regarding their
perception of their children’s behavior, before and after the sup-
plementation period. There were signiﬁcant differences between
studygroupsatbaselineintwoof thethreescales,indicatingworse
ADHD behavior in the omega-3 group. There were also signiﬁ-
cant differences between groups at trial end in all scales, again in
the direction of worse behavior. However, there were no signiﬁ-
cant between-group differences in the changes from pre- to post-
supplementation values in any of the measured parameters.
TEACHER QUESTIONNAIRES
Table 2 presents data from teacher questionnaires,regarding their
perception of the children’s classroom behavior, before and after
the supplementation period. There were no signiﬁcant differences
betweenstudygroupsatbaselineorattrialendinanyof thetested
parameters.Additionally,therewerenosigniﬁcantbetween-group
differences in the changes from pre- to post- supplementation
values in any of the measures.
DSM criteria
Scores of DSM-criteria questionnaires also did not differ between
placeboandomega-3groups.Respectivescoresatbaselinewere11
(range 6–17) and 13 (range 6–17), p = 0.29, with no measurable
change in any of the values at trial end [11 (range 6–17) and 13
(range 6–17), p = 0.47].
COMPUTERIZED CONTINUOUS PERFORMANCE TEST
Table 3 presents data from the MOXO-CPT that the children
undertook before and after the supplementation period. There
were no signiﬁcant differences between study groups at baseline
or at trial end in any of the tested parameters. Additionally, there
werenosigniﬁcantbetween-groupdifferencesinthechangesfrom
pre- to post- supplementation values in any of the measures.
DISCUSSION
The aim of this study was to examine if supplementation
with an oil rich in ALA can improve behavior and function
in children and adolescents with ADHD. Using several vali-
dated questionnaires and a CPT, we found no evidence for a
signiﬁcant effect in any direction. Although we did identify
signiﬁcantly higher post-supplementation scores in the par-
ent Conners’ questionnaires in the omega group, these were
attributed to baseline differences; there were no signiﬁcant differ-
ences between the changes in these questionnaire scores between
groups. A decrease in the parent Conners’ DSM-IV question-
naire score was seen in the placebo group only, with no other
index of improvement in any other measure in this group.
We believe that this does not truly reﬂect clinical improve-
ment, and is probably a random ﬁnding resulting from multiple
comparisons.
Several previous studies of ﬁsh oil/long chain omega-3 sup-
plementation to children with ADHD have been performed, with
recent meta-analyses showing no signiﬁcant clinical effect (Bloch
and Qawasmi, 2011; Gillies etal., 2012). It should be noted
that one meta-analysis on this topic did identify a small, sta-
tistically signiﬁcant effect – but which is clinically much lesser
than that obtained by methylphenidate and other medications
(Bloch and Qawasmi, 2011). Therefore, from a clinical point of
view, there is currently no evidence to support choosing omega-
3 fatty acids over methylphenidate for ADHD treatment. The
authors explained the discrepancy between their own ﬁndings
and the null effect seen in most individual trials, by the small
sample sizes used in the single studies. They calculated that in
order to obtain sufﬁcient statistical power to identify the small
effect of omega-3 in ADHD compared to placebo, clinical tri-
als would require a sample of approximately 330 children. The
authors stated that the omega-3 fatty acid supplementation trials
examiningchildhoodADHDused26–117participantsonly. Con-
versely, the Cochrane meta-analyses (Gillies etal., 2012), which
included 13 trials with 1011 participants overall, concluded that
there is little evidence that omega-3 fatty acid supplementation
provides any beneﬁt for the symptoms of ADHD in children and
adolescents.
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Table 1 | Data from parent Conners’ questionnaires at baseline and study end in both groups.
Placebo(n = 9) Omega-3(n = 8) p-value between changes***
Pre Post p-value Pre Post p-value
Parent Conners’
ADHD Index
62
[47–70]
62
[46–64]
0.19 76*
[71–90]
79**
[54–89]
0.68 0.79
Parent Conners’
Global Index
68
[49–80]
71
[42–76]
0.50 85*
[78–90]
77**
[72–90]
0.46 0.42
Parent Conners’
DSM-IV: total
65
[50–79]
62
[45–69]
0.04 78
[63–89]
87**
[64–90]
0.89 0.22
Data is presented as median and [range].
*Signiﬁcantly different (p< 0.05) from the corresponding baseline value of the placebo group.
**Signiﬁcantly different (p< 0.05) from the corresponding post-supplementation value of the placebo group.
***p-value of the comparison between the pre-post changes in each group.
Table 2 | Data from teacher Conners’ questionnaires at baseline and study end in both groups.
Placebo(n = 9) Omega-3(n = 8) p-value between changes*
Pre Post p-value Pre Post p-value
Teacher Conners’
ADHD index
59
[59–75]
61
[59–69]
0.27 69
[53–89]
69
[58–87]
0.67 0.26
Teacher Conners’
Global Index
63
[60–64]
64
[60–85]
0.65 65
[58–68]
72
[56–90]
0.25 0.76
Teacher Conners’
DSM-IV: total
62
[57–75]
61
[57–67]
0.18 63
[46-90]
66
[56–90]
0.28 0.17
Data is presented as median and [range].
*p-value of the comparison between the pre-post changes in each group.
Table 3 | Data from the MOXO performance test at baseline and study end in both groups.
Placebo(n = 9) Omega-3(n = 8) p-value between changes*
Measure Pre Post p-value Pre Post p-value
Timing 167
[114–253]
158
[54–208]
0.87 125
[23–194]
178
[130–214]
0.14 0.20
Reaction time 0.47
[0.39–0.60]
0.54
[0.10–0.65]
0.50 0.54
[0.05–0.67]
0.52
[0.42–0.66]
0.89 0.88
Impulsivity 14
[2–130]
7
[1–96]
0.73 7
[0–23]
21
[5–157]
0.14 0.20
Attention 230
[166–264]
244
[58–263]
1.00 178
[24–258]
242
[196–256]
0.22 0.53
Hyperactivity 48
[7–293]
29
[0–435]
0.50 20
[4–151]
61
[10–569]
0.35 0.27
Data is presented as median and [range].
*p-value of the comparison between the pre-post changes in each group.
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To our knowledge, only two studies that utilized plant-based
omega-3 fatty acids in ADHD were published to-date (Joshi etal.,
2006; Raz etal., 2009). Both used relatively small amounts of
ALA (200 and 120 mg, respectively). In the study by Joshi etal.
(2006), increased levels of circulating EPA and DHA were found,
demonstrating that even a much lower dose than that used in
our study (yet when combined with vitamin C), is sufﬁcient to
increase concentrations of omega-3 fatty acids in the body. The
improvement seen in most measures in that study, such as total
hyperactivity score, restlessness, impulsiveness, and inattentive-
ness, was very large, around 1 SD. Nevertheless, the lack of
placebo-control group and the addition of vitamin C, prevent
from isolating the individual effect of ALA per se. Collectively,
there is still a wide gap in our knowledge regarding the effects of
omega-3 fatty acids in ADHD, which is even greater in the ﬁeld
of plant-based ALA. The main reasons are the large variations in
the types of fatty acids used (omega-3 with or without omega-6,
ﬁsh- or plant-based oils,etc.),in their dosages,in the proportions
between EPA and DHA, and in the different characteristics and
numbers of participants in each study.
We recognize that our trial has several limitations. Firstly,
we had a relatively small sample size with a high dropout rate,
attributed both to the reported inconvenience of consuming 2 g
of oil per day, and to the subjective feeling of a lack of effect
by the participants or their parents. Recruiting a larger sam-
ple size of newly diagnosed, non-medicated children for such
a trial may be a challenge, as many parents do request an
immediate and efﬁcient treatment once their child is initially
diagnosed with ADHD. Secondly, we chose a wide age range
of 6.5–16 years, which might have caused a wide variation in
test results, especially in the computerized test. Baseline data
of the DSM questionnaire also showed a wide range of dis-
turbance, as reﬂected by the range of DSM scores seen. We a
priori chose a wide age range and included participants from
both sexes in order to increase generalizability, yet eventually
this might have been a drawback. Lastly, the dose used might
have still been too low to increase the amount of brain EPA and
DHA. While this dose has been shown to elevate omega-3 fatty
acids concentrations in red blood cells in adults (Barceló-Coblijn
etal., 2008), we would expect at least the same effect in children
and adolescents; however, examining the brain content of these
fatty acids in children following supplementation is currently not
possible.
The strengths of the study were its randomized, placebo-
controlleddesign;thechoiceof non-medicated,otherwisehealthy
children; and the concomitant use of several validated tools that
directlyassessedthechild,aswellasparentandteacherperceptions
of his behavior.
In summary, in this study, supplementation of 1 g/day of ALA
using anALA-rich oil to children and adolescents withADHD did
notimproveanybehavioralmeasure,astestedbyseveralvalidated
questionnaires and a computerized CPT. We do acknowledge that
a major limitation to the trial was the relatively small sample size,
attributedtoarelativelyhighdropoutrate. Nevertheless,ourﬁnd-
ings are in concert with many other studies which used both ALA
and long-chain omega-3 fatty acids. Given the high dropout rate,
and in light of previous research and anticipated effect size, we
recommend recruiting much larger numbers of participants, and
possibly using a higher ALA dose in future similar studies.
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